Based on the above data showing an immunosuppressive phenotype in our unique mouse model of CRC, we next tested whether administration of single-agent anti-PD-L1 therapy at an early stage of tumor progression can effectively control intestinal tumor growth and improve survival of ApcMin/+; p16cis/cis mice. This evidence concerns the gene CD274 and neoplasm.